Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ICP-332 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ICP-332 Tablets | Drug | Eligible patients will receive ICP-332 tablets orally as per the protocol |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with Adverse Events (AEs) | Up to Day 28 | |
| Number of Participants With Clinically Significant Change in Vital Signs | Up to Day 28 | |
| Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) | Up to Day 28 | |
| Number of Participants With Clinically Significant Change in Physical Examination | Up to Day 28 | |
| Number of Participants With Clinically Significant Change in Clinical Laboratory Values | Up to Day 28 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pharmaron CPC Inc. | Baltimore | Maryland | 21201 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
| ICP-332 Placebo Tablets |
| Drug |
Eligible patients will receive ICP-332 placebo tablets orally as per the protocol |
|